Welcome to our dedicated page for Protagenic SEC filings (Ticker: PTIXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTIXW SEC filings page is closely tied to the regulatory disclosures of Protagenic Therapeutics, Inc., whose common stock trades under the symbol PTIX on the Nasdaq Capital Market. While PTIXW itself represents publicly traded warrants, investors typically review the company’s broader SEC filings to understand how clinical progress, strategic transactions, and listing matters may affect both the common stock and the warrants.
Recent 8-K and 8-K/A filings provide detailed information on material events. One 8-K/A explains that on May 15, 2025, Protagenic Therapeutics entered into a Share Exchange Agreement with Alterola Biotech Inc., EMC2 Capital LLC, and the owners of Phytanix Bio, through which it acquired 100% of the issued and outstanding common shares of Phytanix Bio. The filing also notes that Phytanix Bio is treated as the accounting acquirer in a reverse acquisition under ASC 805-40 and describes five preclinical drug candidate assets (PHYX-001 through PHYX-005) obtained in the transaction.
Another 8-K describes a restructuring plan approved by the Board of Directors to transition to a virtual operating model, temporarily suspend expenditures on preclinical programs originating from Phytanix Bio, and focus capital on the company’s highest-priority clinical program or programs, including a Phase 2 clinical trial of PT00114. This filing also discusses changes in executive roles and the company’s intention to pursue strategic alternatives such as partnerships or out-licensing for the paused preclinical assets.
Additional filings, including Form 12b-25 (NT 10-Q) and 8-K reports on Nasdaq communications, outline delayed quarterly reporting related to merger and restructuring accounting, notices of non-compliance with listing rules, and subsequent steps taken to regain and maintain compliance. These documents explain how Protagenic Therapeutics manages its reporting obligations, capital structure, and listing status.
On this page, users can access these SEC filings and use AI-powered summaries to interpret complex sections such as reverse acquisition accounting, restructuring disclosures, and listing rule discussions. The filings also provide context for warrant-related terms originally set out in the company’s registration statements and prospectus for the PTIX and PTIXW offering.
Protagenic Therapeutics, Inc. (PTIX) reported a sharp swing to quarterly net income of
Total assets rose to
Cash used in operations was
The company disclosed a working capital deficit of
Protagenic Therapeutics, Inc. has appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. He brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb, all in the biotechnology and biopharmaceutical space.
Under his employment agreement, Mr. Nichols will receive a base salary of $350,000 and is eligible for an annual target bonus equal to 40% of his base salary. The agreement also provides for a stock option grant equal to approximately 1.0% of the company’s fully diluted share count. The company states there are no special arrangements or family relationships related to his selection and no related-party transactions requiring disclosure.
Protagenic Therapeutics, Inc. filed a Form 12b-25 notifying the SEC it cannot timely file its Quarterly Report on Form 10-Q for the period ended December 31, 2025. The company states it does not expect to file within the five-calendar-day extension under Rule 12b-25. The notice is signed by Alexander K. Arrow, Chief Financial Officer, on February 18, 2026.
Protagenic Therapeutics, Inc. is having its common stock and warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it has followed its own rules and the SEC’s requirements to strike these securities from listing and withdraw their registration on the exchange. The filing lists Protagenic’s principal executive offices in New York and identifies the affected securities as its common stock and warrants.
Protagenic Therapeutics, Inc. filed an amended current report to update a consent exhibit connected to its earlier acquisition of Phytanix Bio. The company previously completed a share exchange in which it acquired 100% of the common and preferred shares of Phytanix, bringing that Nevada corporation under its control.
This latest amendment revises Item 9.01 solely to update Exhibit 23.1, the consent of GreenGrowth CPAs Inc. No other parts of the prior amended report, including the historical and unaudited pro forma financial statements for the combination with Phytanix, are changed.
Protagenic Therapeutics, Inc. (PTIXW) amended a material event report to disclose near-term clinical milestones for its oncology candidate PT00114 and filing of transaction-related pro forma financials. The company expects to complete the multiple-dose portion of the Phase I study for PT00114 and make those results publicly available in Q2 FY2026 (quarter ending September 30, 2025). It also anticipates initiating a Phase IIa study for PT00114 in Q4 FY2026 (quarter ending March 31, 2026). The unaudited pro forma combined statement of operations for the year ended March 31, 2025, related to the described transaction, is filed as Exhibit 99.2 to this Form 8-K/A and is incorporated by reference.
Protagenic Therapeutics, Inc. (PTIXW) received a Schedule 13G/A filed by Bigger Capital Fund, LP; Bigger Capital Fund GP, LLC; and Michael Bigger reporting their relationship to the issuer's Common Stock (CUSIP 74365N202). The filing states that as of August 22, 2025, each Reporting Person owned no shares of the issuer and reported 0% ownership. The filing includes addresses and citizenship information for each Reporting Person and certifications that the securities were not acquired to influence control of the issuer. Signatures executed by Michael Bigger certify the accuracy of the statement.
Protagenic Therapeutics, Inc. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended June 30, 2025 has not yet been filed. The notice does not immediately affect trading of the PTIX common stock or PTIXW warrants on the Nasdaq Capital Market, and the company plans to submit a compliance plan within 60 days, with Nasdaq able to grant up to 180 days from the 10-Q due date.
The company also replaced MaloneBailey, LLP with Green Growth CPAs as its independent registered public accounting firm, with no reported disagreements or other reportable events, although MaloneBailey’s 2024 report included a going concern explanatory paragraph. In addition, Protagenic announced completion of first-dose injections for all subjects in the multiple-dose part of its Phase I trial of PT00114, expects topline safety data by the end of September 2025, and is planning Phase 2 efficacy studies for the first quarter of 2026.
Protagenic Therapeutics, Inc. filed a notice that it will submit its Quarterly Report on Form 10-Q for the period ended June 30, 2025 after the normal deadline. The company explains that on August 8, 2025 its Board of Directors approved a restructuring plan to move to a virtual operating model and to exit or modify certain obligations, and management is still finalizing the related accounting and disclosures under Audit Committee oversight and with external advisors.
The company expects to file the Form 10-Q on or before August 19, 2025, within the five-day extension allowed under SEC rules. Protagenic states that it does not anticipate reporting a significant change in results of operations for the quarter compared with the same period in the prior year.
Protagenic Therapeutics approved a focused restructuring to transition to a virtual operating model and concentrate capital on its lead clinical asset, PT00114. The Board expects this plan to reduce annualized operating expenses by approximately $8 million while pausing preclinical programs (PHYX-001 through PHYX-005) to pursue partnerships or out-licensing and conserve cash for the Phase 2 trial. The Company currently expects the Phase 2 for PT00114 to complete in approximately 9 to 12 months, subject to enrollment and customary factors.
The plan eliminates certain executive roles by terminating the employment of the CEO and COO, who remain on the Board, and reduces headcount primarily tied to preclinical, regulatory, and IP functions. The Company expects one-time charges related to the restructuring but cannot yet estimate amounts or timing. The Company also changed its fiscal year-end to March 31.